Colon cancer: Update on adjuvant therapy

Clinical Colorectal Cancer

Volumn 7, Issue 3, 2008, Pages 178-183

  Mano, Max S ^a   Duhoux, François ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Bevacizumab; Capecitabine; Elderly patients; Fluoropyrimidines; Irinotecan; Oxaliplatin

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OXALIPLATIN; PANITUMUMAB; SUNITINIB; TEGAFUR; URACIL;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CYTOTOXICITY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; REVIEW; SEPSIS; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

AGE FACTORS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 44449091598     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.023     Document Type: Review

References (71)

1. Jemal A, Siegel R, Ward E, et al, Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352:2696-704.
3. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage III colon cancer: efficacy results with a median follow-up of 4 years. J Clin Oncol 2005; 23(16 suppl):246s (Abstract 3501).
4. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25:2198-204.
5. Aballea S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007; 109:1082-9.
6. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939-44.
7. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-50.
8. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16:295-300.
9. Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21:2896-903.
10. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25:3456-61.
11. Ychou M, Raoul J, Douillard J, et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J Clin Oncol 2005; 23(16 suppl):246s (Abstract 3502).
12. Van Cutsem E, Labianca R, Hossfeld D, et al. Randomized phase III trial comparing infused irinotecan / 5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). J Clin Oncol 2005: 23(16 suppl):3s (Abstract LBA8).
13. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51.
14. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 2007; 25(18 suppl): 165s (Abstract 4007).
15. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7.
16. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
17. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23:4866-75.
18. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007; 25:4779-86.
19. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
20. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup trial. J Clin Oncol 2006; 24:3347-53.
21. Roth AD, Tejpar S, Yan P, et al. Tissue biomarkers (BIOM) in colon cancer (COC): the translational study on the randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts). J Clin Oncol 2007; 25(18 suppl):169s (Abstract 4022).
22. Bertagnolli MM, Compton CC, Niedzwiecki D, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol 2006; 24(18 suppl):541s (Abstract 10003).
23. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-64.
24. Kohne C, Bajerta E, Lin E, et al. Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. J Clin Oncol 2007; 25(18 suppl):171s (Abstract 4033).
25. Starling N, Cunningham D, Vazquez F, et al. A phase I study of sunitinib in combination with FOLFIRI chemotherapy in treatment-naive, metastatic colorectal cancer. Presented at: 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 319.
26. Schwartzberg LS, Hurwitz H, Stephenson J, et al. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2007; 25(18 suppl):183s (Abstract 4081).
27. Schwartzberg LS, Hurwitz H, Stephenson J, et al. Safety and pharmacokinetics (PK) of AMG 706 with panitumumab and FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2007; 25(18 suppl):183s (Abstract 4081).
28. Vieitez J, Valladares M, Pelaez I, et al. A randomised, placebo-controlled, double-blind phase II study of raltitrexed and gefitinib vs raltitrexed alone as 2nd line chemotherapy in subjects with advanced colorectal cancer (CRC). GON group study (Grupo Oncologico del Norte). J Clin Oncol 2007; 25(18 suppl):626s (Abstract 14523).
29. Zampino MG, Magni E, Massacesi C, et al. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 2007; 110:752-8.
30. Hofheinz RD, Kubicka S, Wollert J, et al. Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). Onkologie 2006; 29:563-7.
31. Vincent M, Kerr I, Dingle B, et al. Capecitabine (X) compared to X + erlotinib (E) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): interim efficacy results from a randomized phase II study. J Clin Oncol 2007; 25(18 suppl):630s (Abstract 14560).
32. Tournigand C, Lledo G, Delord J, et al. Modified (m)FOLFOX7/bevacizumab (B) or modified (m)XELOX/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR). J Clin Oncol 2007; 25(18 suppl):187s (Abstract 4097).
33. Meyerhardt JA, Stuart K, Fuchs CS, et al. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 2007; 18:1185-9.
34. Lacombe DA, Caponigro F, Anthoney A, et al. A phase I study of bortezomib in combination with 5FU/LV plus oxaliplatin in patients (pts) with advanced colorectal cancer (CRC): EORTC 16029. J Clin Oncol 2007; 25(18 suppl):186s (Abstract 4090).
35. Kakeji Y, Oki E, Yoshida R, et al. Phase I/II study of S-1 combined with triweekly irinotecan for advanced or recurrent colorectal cancer. J Clin Oncol 2007; 25(18 suppl):628s (Abstract 14541).
36. Cho B, Choi H, Jeung H, et al. Phase II study of oral S-1 monotherapy in metastatic colorectal cancer after failure of both irinotecan and oxaliplatin-containing regimen. J Clin Oncol 2006; 24(18 suppl):170s (Abstract 3597).
37. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004; 22:3395-407.
38. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-19.
39. Gray RG et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc Am Soc Clin Oncol 2004; 23:246 (Abstract 3501).
40. Anjomshoaa A, Lin Y, Black MA, et al. Poor outcome in colorectal cancer patients harbouring reduced expression of a multi-gene proliferation signature. Ann Oncol 2007; 18(suppl 7):vii11 (Abstract O-002).
41. Capella Munar CG, Van Laar R, Moreno Aguardo V, et al. Prognosis prediction of stage II colon cancer by gene expression profiling. Ann Oncol 2007; 18(suppl 7):vii22 (Abstract O-0037).
42. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007; 25:2205-11.
43. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24:2368-75.
44. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16:549-57.
45. Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. XELODA Colorectal Cancer Group. Eur J Cancer 2002; 38(suppl 2):15-20.
46. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3605-16.
47. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX compared to FOLFOX4: survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25(18 suppl):171s (Abstract 4030).
48. Geissler M, Reinacher-Schick A, Freier W, et al. A randomised phase II study assessing bevacizumab in combination with irinotecan/capecitabine or oxaliplatin/capecitabine as first-line therapy in patients with metastatic colorectal cancer (mCRC): preliminary results of the AIO study group. Presented at: 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 335.
49. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project protocol C-06. J Clin Oncol 2006; 24:2059-64.
50. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94:1122-9.
51. Mayer RJ. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2007; 25:4165-7.
52. Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25:102-9.
53. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345:1091-7.
54. Reddy N, Yu J, Fakih MG. Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. Clin Colorectal Cancer 2007; 6:362-6.
55. Jessup JM, Stewart A, Greene FL, et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294:2703-11.
56. Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002; 20:1192-202.
57. Faithfull S, Deery P. Implementation of capecitabine (XELODA) into a cancer centre: UK experience. Eur J Oncol Nurs 2004; 8(suppl 1):S54-62.
58. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004; 2:274-302.
59. Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (XELODA) in cancer patients. Cancer Chemother Pharmacol 2002; 49:225-34.
60. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004; 15:291-5.
61. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25:1824-31.
62. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
63. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007; 25(18 suppl):170s (Abstract 4028).
64. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol 2006; 24(18 suppl):148s (Abstract 3510).
65. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23:3502-8.
66. Fuchs CS, Marshall J, Mitchell EP, et al. Updated results of BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: updated efficacy data. J Clin Oncol 2007; 25(18 suppl):170s (Abstract 4027).
67. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at: 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract 169a.
68. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
69. Bokemeyer C, Bondarenko I, Makhson A, et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. J Clin Oncol 2007; 25(18 suppl): (Abstract 4035).
70. O'Brien CA, Pollett A, Gallinger S, et al.A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106-10.
71. Yilmaz OH, Valdez R, Theisen BK, et al. PTEN dependence distinguishes hematopoietic stem cells from leukemia-initiating cells. Nature 2006; 441:475-82.